A number of other equities research analysts also recently weighed in on the company. SVB Leerink boosted their price target on DexCom from $465.00 to $485.00 and gave the company an outperform rating in a report on Wednesday. Canaccord Genuity boosted their price objective on DexCom from $435.00 to $500.00 and gave the company a buy rating in a research report on Wednesday. Cowen boosted their price objective on DexCom from $430.00 to $450.00 and gave the company an outperform rating in a research report on Tuesday, July 7th. UBS Group boosted their price objective on DexCom from $335.00 to $400.00 and gave the company a neutral rating in a research report on Wednesday. Finally, Robert W. Baird boosted their price objective on DexCom from $296.00 to $373.00 and gave the company an outperform rating in a research report on Wednesday, April 29th. Seven equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. DexCom currently has an average rating of Buy and a consensus target price of $394.95.
Shares of NASDAQ DXCM opened at $435.54 on Thursday. DexCom has a twelve month low of $138.28 and a twelve month high of $446.50. The company has a current ratio of 7.58, a quick ratio of 5.41 and a debt-to-equity ratio of 1.28. The company has a market capitalization of $41.70 billion, a price-to-earnings ratio of 198.88, a price-to-earnings-growth ratio of 4.74 and a beta of 0.79. The business has a 50 day simple moving average of $410.52 and a 200-day simple moving average of $325.07.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, July 28th. The medical device company reported $0.79 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.48. DexCom had a return on equity of 29.01% and a net margin of 11.93%. The business had revenue of $451.80 million during the quarter, compared to the consensus estimate of $415.21 million. During the same period in the previous year, the business earned $0.08 EPS. The business’s quarterly revenue was up 34.3% on a year-over-year basis. As a group, equities analysts predict that DexCom will post 2.45 earnings per share for the current year.
In other news, EVP Jacob Steven Leach sold 19,129 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $376.76, for a total value of $7,207,042.04. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Steven Robert Pacelli sold 1,531 shares of the business’s stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $427.31, for a total value of $654,211.61. Following the completion of the sale, the executive vice president now directly owns 51,482 shares in the company, valued at approximately $21,998,773.42. The disclosure for this sale can be found here. Insiders sold a total of 63,293 shares of company stock worth $24,266,963 in the last three months. Company insiders own 0.69% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of DXCM. Cognios Capital LLC bought a new stake in shares of DexCom in the 1st quarter worth $26,000. Weaver Consulting Group acquired a new stake in shares of DexCom during the first quarter worth $27,000. Nvwm LLC acquired a new stake in shares of DexCom during the first quarter worth $27,000. Flagship Harbor Advisors LLC raised its position in shares of DexCom by 214.3% during the first quarter. Flagship Harbor Advisors LLC now owns 110 shares of the medical device company’s stock worth $30,000 after purchasing an additional 75 shares during the period. Finally, Salomon & Ludwin LLC acquired a new stake in shares of DexCom during the first quarter worth $35,000. 97.08% of the stock is currently owned by institutional investors.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Further Reading: Are all No-Load Funds Equal?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.